Isoplexis

40 articles with Isoplexis

• IsoPlexis acquires extensive DNA and RNA sequencing portfolio to enable integrated single-cell sequencing and proteomic solutions

  5/25/2021

  The integration of the sequence of each single cell coupled with IsoPlexis' proprietary functional proteomics accelerates insights into discovery biology & development of advanced medicines

• IsoPlexis Partners with Bucher Biotec to Expand into Switzerland Market

  5/18/2021

  IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe.

• IsoPlexis Strengthens Commercial Leadership with the Appointment of Jason Ou as Asia-Pacific General Manager

  5/13/2021

  IsoPlexis, the leader in single-cell proteomics, announced that Jason Ou has joined the company as General Manager for the Asia-Pacific region.

• Fierce Medtech Names IsoPlexis as One of its "Fierce 15" Companies of 2020

  3/8/2021

  IsoPlexis announced that it has been named by Fierce Medtech as one of 2020's Fierce 15, designating it as one of the most promising private companies in the industry.

• IsoPlexis' IsoSpark Wins 2021 BIG Innovation Award

  1/12/2021

  IsoPlexis announced that its IsoSpark system has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.

• IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors

  1/7/2021

  Funding to accelerate global expansion of installed base and deliver new solutions at the convergence of single-cell biology and proteomics

• IsoPlexis to Present at Citi's Spotlight on Diagnostics on December 17, 2020

  12/8/2020

  IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Citi's Spotlight on Diagnostics on Thursday, December 17th

• The Scientist Names IsoPlexis Single Cell Intracellular Proteome a Top 10 Innovation of 2020

  12/2/2020

  IsoPlexis' Single-Cell Intracellular Proteome solution has been recognized for its impact on the development of better targeted and edited therapies and its potential to innovate and accelerate medical research

• IsoPlexis to Present at Evercore ISI's 3rd Annual HealthCONx Conference on December 2, 2020

  11/25/2020

   IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay , will present at Evercore ISI's 3 rd Annual HealthCONx Conference on Wednesday, December 2 nd at 9:40 a.m. ET .

• IsoPlexis' Blood-Based Biomarker Predicts Response and Progression-Free Survival to a Novel IL-2 Agonist and Checkpoint Inhibitor Doublet Therapy in a Phase 2 Study of Metastatic Melanoma Patients

  11/12/2020

  IsoPlexis' single-cell proteomics was shown to be a non-invasive and predictive biomarker of response data presented at SITC 2020 Annual Meeting for the PIVOT-02 Trial

• IsoPlexis Launches Personalized Lab System, the IsoSpark, to Continue Scaling to Many Labs Worldwide

  11/11/2020

  The new IsoSpark instrument makes IsoPlexis' unique functional proteomics accessible to every lab, providing an integrated and flexible solution for accelerating curative medicines.

• IsoPlexis and Yale Partner to Advance COVID-19 Immune Profiling Biomarkers

  10/8/2020

  Yale University to use IsoPlexis' single-cell immune landscaping & high-plex automated immunoassay solutions to conduct blood-based immune profiling in COVID-19 and identify rapid circulating markers   [08-October-2020]   BRANFORD, Conn. , Oct. 8, 2020 /PRNewswire/ -- IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with Yale

• IsoPlexis Announces "Single-Cell Proteomics Grant Challenge: COVID-19"

  8/25/2020

  IsoPlexis, the leader in single-cell proteomics, today announced their Single-Cell Proteomics COVID-19 Grant Challenge, where researchers are invited to share next generation insights using single-cell functional proteomics for the opportunity to win 12 IsoCode or CodePlex chips for a project run on the IsoLight system.

• IsoPlexis Announces Partnership with Medquest for IsoLight Expansion into Singapore and Malaysia

  8/25/2020

  IsoPlexis partners with Medquest to expand its single-cell proteomic analysis platform, the IsoLight system and IsoCode & CodePlex Chips, throughout the pharmaceutical and life science markets in Malaysia and Singapore   [25-August-2020]   BRANFORD, Conn. , Aug. 25, 2020 /PRNewswire/ -- IsoPlexis, the leader in single-cell proteomics products, today announced an exclu

• IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing

  8/20/2020

  - Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platform - IsoLight® to be used for functional quality analytics for cell therapy products produced on Lonza's Cocoon® Platform, an automated cell manufacturing platform   [20-August-2020]   BASEL, Switzerland and BRANFORD, Conn. , Aug. 20, 2020 /PRNewswire/ -- Quote from Matthew Hewitt , Hea

• IsoPlexis Adds Partnership to Advance COVID-19 Vaccine Development

  8/14/2020

   IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with the Division of Infectious Diseases, Department of Medicine at Columbia University, IsoPlexis' Single-Cell Secretome immune profiling solutions will be used to study cellular drivers of durable and protective immune response to COVID-19.

• IsoPlexis Announces Partnership with Neoline Technology Co & IsoLight Expansion into Chinese Life Science Market

  7/28/2020

  IsoPlexis partners with Neoline to extend sales of its single-cell proteomic analysis platform, IsoLight and IsoCode & CodePlex Chips, to the pharmaceutical and life science markets in China

• IsoPlexis Strengthens Commercial Leadership with the Appointment of Peter Siesel as Chief Commercial Officer

  6/26/2020

  IsoPlexis, the leader in single-cell proteomics, today announced that Peter Siesel has joined the company as Chief Commercial Officer. In this role, Mr. Siesel will continue to advance IsoPlexis' commercialization and market expansion efforts by leading global sales and customer support, as well as expansion into key regions for ma

• IsoPlexis Awarded $2 Million NIH Phase 2 SBIR Grant for Expanding Development of a Cellular Platform for Analyzing the Peripheral Immune Response in Alzheimer's Disease and Neuroinflammation with Single-cell Proteomics

  6/9/2020

  IsoPlexis secures grant funding to expand Alzheimer's applications using functional single-cell proteomics on the IsoLight system

• IsoPlexis Strengthens Executive Leadership Team with Appointment of John Strahley as Chief Financial Officer

  5/11/2020

  IsoPlexis, the leader in functional cellular proteomics, today announced the appointment of John Strahley as Chief Financial Officer.